# OnCo record nct05246514 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05246514/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05246514", "NCT05246514" ;
  schema:name "A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC"@en ;
  schema:alternateName "DESTINY-Lung05"@en ;
  schema:description "A phase 2 trial of Trastuzumab deruxtecan in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05246514/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05246514> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2022-07-13" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/her2-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct05246514-clin-lung-cancer-2026/> .